L-NMMA

DRUG16 trials

Sponsors

National Institutes of Health Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University, Radboud University Medical Center, The University of Texas Medical Branch, Galveston

Conditions

Classical Hodgkin LymphomaDNA Repair-Deficiency DisordersEndotoxemiaHER2-negative Breast CancerHIVHead and Neck Squamous Cell CarcinomaHealthyHypercapnia

Phase 1

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

CompletedNCT00072826

National Institutes of Health Clinical Center (CC)Sickle Cell Disease

Start: 2003-11-04End: 2007-08-24Updated: 2019-12-12

The Effect of Lopinavir/Ritonavir on Endothelial Function

CompletedNCT00076414

National Institutes of Health Clinical Center (CC)Healthy

Start: 2004-01-31End: 2005-09-30Target: 30Updated: 2008-03-04

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

CompletedNCT00095472

National Heart, Lung, and Blood Institute (NHLBI)Sickle Cell Anemia

Start: 2004-11-01End: 2007-08-24Updated: 2019-11-05

Blockade of Vascular Potassium Channels During Human Endotoxemia

CompletedNCT00185003

Radboud University Medical CenterEndotoxemia

Start: 2003-01-31End: 2005-06-30Updated: 2008-10-17

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

TerminatedNCT00327080

National Heart, Lung, and Blood Institute (NHLBI)HIV

Start: 2006-05-12End: 2009-03-18Updated: 2019-12-17

Insulin and Sarcopenia in the Elderly

CompletedNCT00690534

The University of Texas Medical Branch, GalvestonSarcopenia

Start: 2005-09-30End: 2012-08-31Updated: 2016-12-12

Pathophysiology of Cardiometabolic Risk Factors in African Americans

CompletedNCT01122407

Vanderbilt University Medical CenterHypertension, Obesity

Start: 2010-01-31End: 2016-11-30Updated: 2017-01-18

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

CompletedNCT02834403

The Methodist Hospital Research InstituteMetastatic Triple Negative Breast Cancer

Start: 2016-11-30End: 2021-01-31Updated: 2023-12-15

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

WithdrawnNCT03066115

University of Wisconsin, MadisonHypercapnia, Hypoxia

Start: 2020-12-01End: 2021-12-01Updated: 2019-01-10

Phase Ib of L-NMMA and Pembrolizumab

Active, not recruitingNCT03236935

The Methodist Hospital Research InstituteClassical Hodgkin Lymphoma, DNA Repair-Deficiency Disorders, Head and Neck Squamous Cell Carcinoma +3

Start: 2018-08-03End: 2025-12-28Updated: 2025-03-10

Phase 2

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

CompletedNCT00009581

National Institutes of Health Clinical Center (CC)Sickle Cell Anemia

Start: 2001-01-31End: 2003-01-31Target: 65Updated: 2008-03-04

Niacin to Improve Blood Flow in People With Sickle Cell Disease

CompletedNCT00508989

National Heart, Lung, and Blood Institute (NHLBI)Sickle Cell Disease

Start: 2007-07-24End: 2015-12-24Updated: 2020-09-10

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

RecruitingNCT05660083

The Methodist Hospital Research InstituteHER2-negative Breast Cancer, Metaplastic Breast Carcinoma, Metastatic Breast Cancer +1

Start: 2023-01-12End: 2028-12-02Target: 36Updated: 2026-04-03

Phase 4

Effect of DPP4 Inhibition on Growth Hormone Secretion

CompletedNCT01701973

Vanderbilt UniversityObesity

Start: 2013-01-31End: 2017-05-31Updated: 2018-05-29

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

CompletedNCT01744236

Amsterdam UMC, location VUmcType 2 Diabetes

Start: 2013-04-30End: 2015-08-31Updated: 2015-12-09

Unknown Phase

Nitric Oxide and the Autonomic Nervous System

CompletedNCT00178919

Vanderbilt UniversityHypertension, Pure Autonomic Failure

Start: 2002-08-31End: 2008-08-31Updated: 2013-06-04

Related Papers

Complete autonomic blockade reveals nitric oxide contribution to blood pressure regulation in obese Black women

Clinical Autonomic Research2024-08-01

Abstract 3447: NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer

Cancer Research2023-04-04

Abstract P4-08-05: NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer

Cancer Research2023-03-01

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes

Diabetes & Metabolism2021-01-1259 citations

Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women

Journal of the American Heart Association2018-02-269 citations

Abstract CT037: Clinical phase Ib trial of L-NMMA plus docetaxel in the treatment of refractory locally advanced or metastatic triple negative breast cancer patients

Cancer Research2017-07-013 citations

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

2016-09-15114 citations

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

2016-08-3046 citations

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia2016-04-01124 citations

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

BMJ Open2015-11-0130 citations

A moderate acute increase in physical activity enhances nutritive flow and the muscle protein anabolic response to mixed nutrient intake in older adults.

2012-05-0999 citations